Leadership Team
Scientific Excellence. Strategic Vision. Proven Execution.
Epi One's leadership team brings together deep expertise in molecular diagnostics, cancer biology, clinical development, and business strategy. United by a shared vision to advance precision oncology, our leaders combine scientific innovation with commercial insight to accelerate the translation of breakthrough technologies into impactful diagnostic solutions.
Sophia F. Fang, MD & PhD
CEO, President & CSO
With both MD and Ph.D. training, Sophia brings a proven record of translating cutting-edge research into clinical success.
Dr. Fang leads the company’s scientific strategy, research operations, business development, and team growth, while also serving as Chair of the Board, guiding Epi One’s long-term strategic direction and commercial expansion. Prior to co-founding Epi One, Sophia was a senior scientist at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. Her research was focused on human genomics and translational cancer biology. Sophia has an MD from Harbin Medical University and a Ph.D. in Bioinformatics and Computational Biology from Iowa State University and serves as Chair of Epi One's Board of Directors.
.
Neng Yang, MD & PhD
Co-Founder, Senior Vice President R&D
Dr. Yang leads cross-functional execution spanning product translation, CLIA strategy & build-out, regulatory strategy, and clinical evidence generation supporting corporate financing and market scale.
Dr. Yang conducts day-to-day experiments for the cancer detection biomarkers’ clinical validation. Prior to co-founding Epi One she was a research associate at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. She established a novel single cell sorting and sequencing technology to understand the genetic heterogeneity of leukemia. She also conducted research on CAR T-cell therapy for lung cancer patients. Neng has an MD from Guangdong Medical College and a Ph.D. from ShangHai JiaoTong University and serves on Epi One's Board of Directors.
MinKui Luo, PhD
Dr. Luo is a full professor at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He is interest in discovery research at the interface of chemistry and biology. Specifically, Dr. Luo focuses on studying epigenetic writers (PMTs), readers (Rme/Kme effectors) and erasers (demethylases) with functional relevance to noncanonical histone methylation, protein homeostasis and transcription plasticity
John Meduri, MBA, MS, MT(ASCP)
John J Meduri is an in-vitro diagnostics (IVD) industry veteran with over 40 years leading global commercialization, strategic marketing, and business development in the diagnostics and life sciences industries. He has held leadership roles at Becton Dickinson, MRL Pharmaceutical Services and Accelerate Diagnostics with a proven track record of launching transformative IVD platforms, driving M&A activity, and building high-performing global teams.